BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, January 17, 2026
Home » Authors » Peter O'Donnell

Peter O'Donnell

Articles

ARTICLES

Two Of Sanofi's Hepatitis B Vaccines Win EU Clearance

May 17, 2006
By Peter O'Donnell

Two Of Sanofi's Hepatitis B Vaccines Win EU Clearance

May 17, 2006
By Peter O'Donnell

European Union Makes Bid To Boost Biotech Start-ups

May 10, 2006
By Peter O'Donnell

European Union Makes Bid To Boost Biotech Start-ups

May 10, 2006
By Peter O'Donnell

Rivalry Resurfaces Among EU Biotechnology Trade Groups

May 3, 2006
By Peter O'Donnell

Rivalry Resurfaces Among EU Biotechnology Trade Groups

May 3, 2006
By Peter O'Donnell

Omnitrope Approved, Becomes First 'Biosimilar' Cleared In EU

April 26, 2006
By Peter O'Donnell

Omnitrope Approved, Becomes First 'Biosimilar' Cleared In EU

April 26, 2006
By Peter O'Donnell

Biotech Firms Want More Incentives For EU Orphans

April 12, 2006
By Peter O'Donnell

Biotech Firms Want More Incentives For EU Orphans

April 12, 2006
By Peter O'Donnell
View All Articles by Peter O'Donnell

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 16, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 16, 2026.
  • SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

    BioWorld Science
    Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
  • Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

    BioWorld
    With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
  • Businesswoman pressing dollar sign on touchscreen

    JPM 2026: Year kicks off with biopharma Q4 revenue and guidance

    BioWorld
    It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing